Orthocell (ASX:OCC) said the US rollout of its nerve repair product Remplir is well ahead of schedule, according to a Friday Australian bourse filing.

The company expects Remplir's US revenue from early surgical cases to grow in the second half of the fiscal year, the filing said.

Orthocell's shares were down almost 3% in recent Friday trade.